INVESTOR PRESENTATION - PHARMAXIS LTD
PHARMAXIS LTD
Health Care
Pharmaxis Limited (PXS) is a specialty pharmaceutical company involved in the research, development and commercialisation of therapeutic products for chronic respiratory disorders. PXS has two approved products: Bronchitol for cystic fibrosis and Aridol diagnosis of asthma; and four products in development: PXS-4728, LOX platform technology Orbital, ASM8. Headquartered in Sydney at its Frenchs Forest manufacturing facilities, Pharmaxis also has offices in Europe and the United States. Former Names Pharmaxis Limited PXS (11/11/2003)
Read moreMarket Cap
31.71m
Price at Close
$0.08
4w avg. Volume
599.12k
4w avg. Turnover
$55.63k
Announcements
| announcement | t+2 movement | date |
|---|---|---|
| - | 17 Sep 2020 |
| -2.44% | 16 Sep 2020 |
| +2.50% | 06 Sep 2020 |
| +1.03% | 02 Sep 2020 |
| +6.06% | 24 Aug 2020 |
| +6.06% | 24 Aug 2020 |
| +6.06% | 24 Aug 2020 |
| -8.70% | 19 Aug 2020 |
| -9.09% | 18 Aug 2020 |
| 0.00% | 14 Aug 2020 |
Market Data
Current Price
$0.08
52WK HIGH
$0.285
52WK LOW
$0.053
1YR RETURN
-63.64%
1YR RETURN VS. SECTOR
-103.04%
90 DAY RETURN
+15.94%
ASX RANK
1,219
/2,019
SECTOR RANK
21
/31
SHARES OUTSTANDING
396.41m
PHARMAXIS LTD
Health Care
Pharmaxis Limited (PXS) is a specialty pharmaceutical company involved in the research, development and commercialisation of therapeutic products for chronic respiratory disorders. PXS has two approved products: Bronchitol for cystic fibrosis and Aridol diagnosis of asthma; and four products in development: PXS-4728, LOX platform technology Orbital, ASM8. Headquartered in Sydney at its Frenchs Forest manufacturing facilities, Pharmaxis also has offices in Europe and the United States. Former Names Pharmaxis Limited PXS (11/11/2003)
Read moreMarket Cap
31.71m
Price at Close
$0.08
4w avg. Volume
599.12k
4w avg. Turnover
$55.63k
ASX:PXS is not raising right now
Want to invest?
Contact Us
(03) 9028 2888
clients@freshequities.com
Address
Level 7, 388 Bourke St
Melbourne VIC 3000
Australia